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HIV invades the human host and replicates 
preferentially in CD4+ T cells, leading to increasing 
viral numbers and a failing immune system. An 
important feature in the pathogenesis of AIDS is 
chronic immune activation and inflammation. [1-4] 
Sustained immune activation creates a suitable environment 
for viral replication, drives the loss of CD4+ T cells and also 
leads to inflammation-related disorders such as atherosclerosis, 
neurocognitive deterioration, musculoskeletal abnormalities and 
certain cancers.[1-3]
Another complication related to immune activation in HIV is 
the development of peripheral blood cytopaenias. Cytopaenias 
are due, in part, to the stimulated immune system releasing pro-
inflammatory cytokines, which suppress haemopoiesis in the bone 
marrow. Other contributing factors to low cell counts include the 
suppression of bone marrow progenitors by HIV-infected T cells, the 
myelosuppressive effect of certain drugs, infective and malignant bone 
marrow infiltration, and immune-mediated peripheral destruction of 
blood cells.[5-7]
Antiretroviral therapy (ART) is the most effective treatment 
for patients with HIV/AIDS.[1,3,5] The current criteria for initiating 
ART are based on either the presence of an AIDS-defining illness, 
the quantification of CD4+ T cells (or total lymphocyte counts, in 
situations where CD4+ counts are not available) or a combination 
of clinical HIV disease staging and CD4+ (or lymphocyte) counts.[5] 
Once ART is initiated, patients are followed-up at regular intervals 
with clinical examinations, CD4+ counts and viral-load testing.[5] 
Although the degree of immunodeficiency and viral burden are 
monitored routinely, immune activation status is not currently tested 
in HIV infection.[2,4,5] Many serum markers of inflammation or 
immune stimulation in HIV infection have been identified, including 
the well-established cellular marker of immune activation, CD8+ 
T cells that express the activation marker CD38.[1,2,4] CD38 expression 
on CD8+ cells (CD38onCD8) is an important prognostic marker of 
HIV disease progression, independent of immunodeficiency and 
viral burden.[1,4] However, determination of CD38onCD8 expression 
by flow cytometry is an expensive and technically difficult test to 
perform in resource-limited settings.[4,8] 
In 2002, a working group was established to develop an approach 
to clinical research priorities for ART use in resource-limited settings. 
Issues addressed included the timing of initiation of therapy, choice 
of ART agents, adherence to therapy and the monitoring of patients 
receiving treatment. With regard to the latter, the development of simpler, 
more cost-effective tests, which could assess viral burden and immune 
function, to replace viral loads and CD4+ counts was recommended.[9] 
For HIV-infected patients, either prior to or after initiation of ART, 
a full blood count (FBC) and differential count are regularly requested 
owing to the prevalence of cytopaenias, opportunistic infections and 
adverse drug events.[5] The cytopaenias include anaemia, leucopaenia, 
neutropaenia, lymphopaenia and thrombocytopaenia, which may 
exist as isolated features, or in various combinations. [6] Parameters 
routinely included in an FBC are the total white cell count (WCC), 
haemoglobin (Hb) concentration and a platelet count as well as a 
leucocyte differential count. The leucocyte differential count includes 
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Background. A feature of HIV/AIDS is chronic immune activation, which results in a number of complications including inflammation-
related disorders and blood cytopaenias. Immune activation status is not routinely tested in HIV infection. However, the full blood count 
(FBC) is a commonly performed test.
Objective. We hypothesised that FBC parameters would be significantly different in HIV-infected v. -uninfected individuals, and that some 
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HIV-uninfected adults. The %CD38onCD8 and CD4+ counts were determined by flow cytometry and the FBC was performed on a Siemens 
ADVIA 2120 system. FBC parameters investigated were total white cell count (WCC), haemoglobin (Hb) concentration, platelet count, 
absolute neutrophil count, absolute lymphocyte count, and percentage of large unstained cells (%LUCs).
Results. Significant differences were found between the HIV-infected and -uninfected groups for total WCC, Hb, neutrophil count, 
lymphocyte count and %LUCs. The mean ± standard deviation (SD) for the total WCC (5.3±1.3 v. 6.9±2.2; p≤0.001) and the %LUCs 
(2.5±0.9 v. 2.0±0.9; p=0.001) both showed correlations with CD4+ counts and %CD38onCD8. 
Conclusion. The total WCC and %LUCs showed significant differences in HIV-infected individuals and correlated with markers of immune 
activation and disease progression. This suggests the potential use of these parameters as markers of immune activation in HIV infection.
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the neutrophil, lymphocyte, monocyte, eosinophil and basophil 
counts. On certain haematology analysers, (i.e. the Siemens ADVIA 
2120) the percentage of large unstained cells (%LUCs) also forms part 
of the differential count. LUCs usually encompass virally activated 
lymphocytes, plasma cells, hairy cells, paediatric lymphocytes and 
peroxidase-negative blasts.[10] The FBC is an affordable test available 
in most intermediate (level 2) and central (level 3) laboratories.[5] 
Furthermore, it is recommended that if CD4+ counts are not available, 
total lymphocyte counts, performed as part of the differential count 
on routine haematology analysers[5,10] may be seen as a surrogate 
marker of immune function.
Objective
To determine whether certain FBC parameters are significantly 
different in HIV-infected patients v. uninfected individuals, and 
whether these parameters correlate with markers of HIV disease 
progression and immune activation in an untreated local population 
group. We hypothesised that the WCC, platelet count and Hb 
concentration would be lower in the HIV-infected cohort, and that 
the %LUCs would be raised. We further hypothesised that these 
FBC parameters would correlate with CD4+ counts, viral loads and 
%CD38onCD8. A secondary objective of the study was to determine 
whether testing of FBC parameters would be more affordable than 
%CD38onCD8 determination. 
Methods 
Study design
This was a cross-sectional study of 134 adults recruited from a single 
HIV counselling and testing (HCT) clinic in Crossroads, Cape 
Town, South Africa. The prevention clinic employs the national 
HCT algorithm with accredited rapid tests. Study participants were 
recruited between May 2010 and June 2012 and were enrolled in the 
study after confirmation of HIV status and before referral for further 
management. Exclusion criteria were: individuals <21 years of age, 
patients receiving ART, features of tuberculosis (TB) or individuals 
receiving anti-TB therapy or other medications, and symptoms of 
systemic illness (as assessed by a clinic nurse). Peripheral blood was 
drawn from all patients and used to measure the FBC and differential 
count, %CD38onCD8, the CD4+ count and the viral load (the latter 
tested in the HIV-infected study participants only).
The study was approved by the Stellenbosch University Human 
Research Ethics Committee (ref no. N07/09/197) and the University 
of Cape Town Research Ethics Committee (ref no. 417/2006), and 
performed in accordance with the Declaration of Helsinki. 
Whole blood analysis
Whole blood was analysed on a Siemens ADVIA 2120 system, which 
makes use of cytochemistry and flow cytometry systems. Hb was 
measured by modification of the cyanmethaemoglobin method 
together with a cell-based method. Platelets were analysed using two 
angles of light scatter, used to calculate the volume and refractive 
index. A combination of cell size, myeloperoxidase staining and 
nuclear lobulation was used to perform the total leucocyte and 
6-part differential count. We assessed the following parameters: the 
total WCC, absolute neutrophil and absolute lymphocyte count, 
and %LUCs. LUCs are peroxidase-negative cells, which do not fit 
into the other categories of leucocytes, i.e. neutrophils, monocytes, 
eosinophils, lymphocytes and basophils.
The %CD38onCD8 was determined by flow cytometry. Heparinised 
whole blood was processed on the same day as the sample was drawn. A 
total of 50 μl of whole blood was incubated with the following mono clonal 
antibodies: CD8-PerCP; CD38-APC; CD3-FITC (BD Biosciences) for 20 
minutes at room temperature. The red blood cells were lysed in BD FACS 
Lyse and the remaining cells washed with staining buffer (2% fetal calf 
serum in phosphate-buffered saline) prior to acquisition and analysis on a 
BD FACSCalibur instrument using BD Cell Quest Pro (version 2) software. 
Lymphocytes were gated on forward v. side scatter and CD3 expression, 
and %CD38onCD8 within the lymphocyte gate was determined.
Flow cytometry for CD4+ T cell counts was performed using whole 
blood. The BD MultiTEST CD3-FITC/CD8-PE/CD45-PerCP/CD4-
APC reagent together with TruCOUNT tubes (BD Biosciences) was 
used for determining CD4+ counts. 
HIV-1 RNA quantifications for viral load testing were performed using 
1 ml of plasma with the Nuclisens Easy Q HIV-1 v.1.2 kit (BioMerieux 
Inc), an assay with a lower detection limit of 40 - 50 copies/ml.
Statistical analysis
The Mann-Whitney U test was used to determine differences between 
the means, standard deviations and 95% confidence intervals (CIs). 
The Spearman rank order method was used to identify correlations 
between the FBC parameters and the established markers, which 
were %CD38onCD8, CD4+ count and viral load.
Costing
Although a complete cost analysis was not carried out, we compared 
the pricing of these tests based on how much it would cost the 
consumer in our setting. In SA, state-funded laboratory testing is 
performed by the National Health Laboratory Service (NHLS); costs 
quoted below were taken from the Department of Health website.[8]
Results
The 83 HIV-infected individuals were naive to ART, not receiving 
anti-TB or other medication and clinically asymptomatic. Their 
median age was 32 years and there was a female to male ratio of 2.8:1. 
The 51 HIV-uninfected individuals were from the same population, 
with a median age of 31.8 years and a female to male ratio of 2:1. 
Statistically significant differences were found between the HIV-
infected and -uninfected groups for %CD38onCD8, CD4+ counts, 
total WCCs, Hb concentrations, absolute neutrophil counts, absolute 
lymphocyte counts and %LUCs (Table 1). The 95% CIs for total 
WCC and %LUCs are shown in Figs 1 and 2, which demonstrate 
the significant differences, with no overlapping ranges. No statistical 
difference was observed between the HIV-infected and -uninfected 
groups for the platelet count (Table 1). There were significant 
positive correlations between %CD38onCD8 and both %LUCs 
and total WCC, and there was a significant inverse correlation 
between %CD38onCD8 and Hb concentration. There were also 
significant positive correlations between CD4+ counts and the 
absolute lymphocyte count, the absolute neutrophil count and the 
total WCC, and an inverse correlation between the CD4+ count and 
%LUCs (Table 2). 
Although the %CD38onCD8 is not a routinely performed test, it 
is possible to request a flow cytometry-based analysis, which would 
cost R629.40 (~64 USD), based on the number of antibodies used.[8] 
The FBC costs R50.25 (~5 USD) and the leucocyte differential costs 
R27.55 (~3 USD).[8] The total cost of a full blood and differential 
count is R77.80 (~8 USD).[8]
Discussion
Immune activation is an important prognostic factor in HIV 
infection. [1-4] Affordable markers of immune activation would be 
of value in the management algorithms of early HIV infection in 
resource-limited settings. In the current study, of the parameters 
assessed on the FBC, the total WCC and %LUCs demonstrated 
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good potential for future use in this context. The total WCC was 
significantly lower in the HIV-infected group and the %LUCs were 
significantly higher than in the uninfected group, with both markers 
showing clearly defined 95% CIs (Figs 1 and 2). Furthermore, both 
parameters correlated with the CD4+ count (an indicator of HIV 
disease progression) and %CD38onCD8 (an established marker of 
immune activation in HIV infection). 
Leucopaenia in HIV infection is thought to be predominantly 
due to lymphopaenia and neutropaenia.[6,11] Studies have shown 
that lymphopaenia and depletion in lymphocyte subsets correlate 
with markers of immune activation in HIV infection.[11,12] However, 
total WCC has not been previously studied as a potential marker of 
generalised immune activation levels in untreated HIV-infection. In 
this study, we show for the first time that the lower the total WCC, 
the higher the levels of immune activation (%CD38onCD8). This 
is likely to be due to a combination of factors, including the pro-
inflammatory environment in HIV infection, which primes activated 
cells for accelerated death,[1] and suppresses the regeneration of the 
immune system in the bone marrow, thymus and lymph nodes.[1,6] 
Very few studies have focused on the clinical implications of LUCs 
in humans, most assessing LUCs in the context of haematological 
malignancies and not immune activation.[13,14] A study from Europe 
reviewed FBC reports to identify and describe cases with raised LUCs. 
The study found that in the very small percentage (0.007%) of reports 
that identified high numbers of LUCs, the majority of cases (85%) had 
associated viral infections (i.e. Epstein-Barr virus and influenza A) 
while the remaining 15% were associated with chronic renal failure. 
The HIV status of the patients was not reported. It was suggested 
that high numbers of LUCs, where chronic renal failure and acute 
leukaemia have been excluded as a cause, represent natural killer 
cells, cytotoxic lymphocytes or other reactive lymphoid cells. [15] This 
suggests that LUCs represent virally activated lymphocytes, consistent 
with our hypothesis that circulating LUCs would be present in higher 
numbers in individuals with chronic immune stimulation.
Our study found significantly lower neutrophil and lymphocyte 
counts and Hb concentrations in the HIV-infected group. Lower 
blood cell counts/cytopaenias are a common effect of HIV infection 
and mechanisms include decreased bone marrow production and 
increased peripheral destruction of cells. Causes are multifactorial, 
contributing factors include immune activation and release of 
cytokines, effects of ART and opportunistic infections.[6] As all 
individuals in our study were ART-naive and did not show clinical 
features of opportunistic infections, their cytopaenias were most likely 
due to cytokine-induced myelosuppression, or enhanced destruction 
due to immune mechanisms. The significantly raised %CD38onCD8 
found in these individuals adds support to the concept of ongoing 
immune activation as contributing to the cytopaenias.
Some of our findings were comparable with those in a study 
conducted in an HIV-infected, predominantly adult population 
to assess the presence of cytopaenias in relation to CD4+ counts. 
This study found that lower CD4+ counts (<200 cells/μl) were 
associated with a higher prevalence of anaemia, neutropaenia and 
thrombocytopaenia.[7] Our study also found declining CD4+ counts 
associated with lower Hb concentrations and neutrophil counts 
but there were no significant findings in relation to platelet counts. 
Another comparative study, conducted among HIV-positive, ART-
Table 1. Whole blood analysis of HIV-infected v. -uninfected patients
Variable
HIV-infected HIV-uninfected
p-value*Mean±SD 95% CI Mean±SD 95% CI
%CD38onCD8 57.8±19.7 53.5 - 62.1 40.3±16.4 35.7 - 44.9 <0.001†
CD4+ count (cells/μl) 405±177 366 - 444 952±332 859 - 1 045 <0.001†
Total WCC (× 109 cells/l) 5.3±1.3 5.1 - 5.5 6.9±2.2 6.4 - 7.4 <0.001†
Hb concentration (g/dl) 12.7±1.4 12.4 - 13 13.5±1.7 13.1 - 13.9 0.001†
Platelet count (× 109 cells/l) 292±77 278 - 306 301±80 284 - 318 0.429
ALC (× 109 cells/l) 1.7±0.5 1.6 - 1.8 2.1±0.8 1.9 - 2.3 0.010†
ANC (× 109 cells/l) 2.9±1.3 2.6 - 3.2 4.1±1.9 3.7 - 4.5 <0.001†
%LUCs 2.5±0.9 2.3 - 2.7 2±0.9 1.8 - 2.2 0.001†
SD = standard deviation; CI = confidence interval; CD38onCD8 = CD38 expression on CD8+ cells; WCC = white cell count; Hb = haemoglobin; ALC = absolute lymphocyte count;  
ANC = absolute neutrophil count; LUCs = large unstained cells. 
*Mann-Whitney U test.
†Statistically significant, p<0.05.
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Fig. 2. LUCs in the HIV-infected and -uninfected groups (95% CIs).
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naive adolescents, found lower WCCs, 
neutrophil counts and CD4+ counts, as well 
as higher expression of %CD38onCD8.[11] 
There was a significant positive correlation 
between both the %LUCs and the total 
WCC, and %CD38onCD8, the established 
marker of immune activation. 
The total cost of a full blood and differential 
count is R77.80 (~8 USD), compared with the 
%CD38onCD8 price of R629.40 (~64 USD), 
the blood parameters costing approximately 
eight times less.[8] Using total WCC or 
%LUCs, either independently or together, 
could serve as relatively inexpensive markers 
of immune activation in HIV infection.
The clinical consequences of chronic 
immune activation are inflammation-
related conditions, including cardiovascular, 
neurological, musculoskeletal and malignant 
diseases.[1-3] In addition, studies have 
shown that patients receiving ART and 
with suppressed viral loads remain at risk 
of inflammation-related morbidity, owing to 
parameters other than viral burden, which 
drive immune activation. Clinical trials are 
being carried out using adjusted ART regimens 
and anti-inflammatory agents, in an effort 
to boost CD4+ counts and decrease systemic 
immune activation.[2,3] The clinical utility of 
immune activation markers, such as total 
WCC and %LUCs, would be to identify HIV-
infected individuals who are at a greater risk 
of inflammation-related co-morbidities. These 
individuals would then benefit from further 
investigation for underlying inflammatory 
conditions and appropriate management.
A possible limitation of our study was 
its cross-sectional nature, which provided a 
‘snap-shot’ insight into immune activation 
levels. In addition, specific investigations 
for other underlying co-infections were not 
performed. Longitudinal studies will be of 
value to determine the predictive power of 
lower WCCs and raised LUC levels for disease 
progression, development of complications or 
response to various treatment interventions.
Conclusion
The total WCC was significantly decreased 
and %LUCs significantly increased in the 
HIV-infected study population, substan-
tiating the relevance of these markers in 
HIV infection. The correlations observed 
between both total WCC and %LUCs and 
the CD4+ count, support the potential use of 
total WCC and %LUCs as markers of HIV 
disease progression. Furthermore, there were 
significant correlations between both total 
WCC and %LUCs and the %CD38onCD8, 
suggesting that these FBC parameters may 
serve as useful markers of immune activation. 
The FBC and differential count are affordable, 
routinely performed tests, even in resource-
limited settings. Intervention studies will be 
important to determine whether these FBC 
parameters are surrogate markers of immune 
activation in HIV infection.
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Table 2. Spearman Rho rank correlation for FBC parameters against the established 
markers
Variable 1 Variable 2 Spearman Rho p-value*
Total WCC (× 109 cells/l) %CD38onCD8 -0.228 0.008†
CD4+ count 0.484 <0.001†
Viral load -0.073 0.465
Hb concentration (g/dl) %CD38onCD8 -0.206 0.017†
CD4+ count 0.122 0.095
Viral load -0.096 0.336
Platelet count (× 109 cells/l) %CD38onCD8 -0.120 0.168
CD4+ count 0.103 0.160
Viral load -0.217 0.029†
ALC (× 109 cells/l) %CD38onCD8 -0.158 0.089
CD4+ count 0.556 <0.001†
Viral load -0.111 0.291
ANC (× 109 cells/l) %CD38onCD8 -0.166 0.074
CD4+ count 0.353 <0.001†
Viral load -0.088 0.402
%LUCs %CD38onCD8 0.397 <0.001†
CD4+ count -0.248 0.006†
Viral load 0.151 0.208
FBC = full blood count; WCC = white cell count; CD38onCD8 = CD38 expression on CD8+ cells; Hb = haemoglobin;  
ALC = absolute lymphocyte count; ANC = absolute neutrophil count; LUCs = large unstained cells.
*Spearman Rho rank correlation
†Statistically significant, p<0.05.
